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1. Introduction 
The word sepsis was derived from the Greek word: sêpsis, which means the state of putre-
faction or decay. Sepsis is a potentially deadly medical condition that is characterized by a 
whole-body inflammatory state, called a systemic inflammatory response syndrome, and 
the presence of a known or suspected infection. The more critical subsets of sepsis are severe 
sepsis with acute organ dysfunction, hypoperfusion, or hypotension and septic shock with 
refractory arterial hypotension despite adequate fluid resuscitation [1, 2]. Because the mo-
lecular pathogenesis of sepsis is incompletely understood and its specific and effective ther-
apies are lacking, sepsis is still a major cause of death in intensive-care units worldwide, 
with mortality rates that range from 20% for sepsis, through 40% for severe sepsis, to over 
60% for septic shock [3, 4]. More knowledge of the pathophysiology of sepsis is needed if we 
are to develop better, more effective interventions to sepsis. It has been increasingly recog-
nized that genetic factors influence individual susceptibility, severity and outcome in sepsis 
[5, 6]. Identification of new genetic factors in sepsis may hold promise for new mechanistic 
insights and new therapeutic modalities. 
Nicotinamide phosphoribosyltransferase (NAMPT) is emerging as a risk factor in sepsis. 
NAMPT is a pleiotropic protein. It catalyzes the condensation of nicotinamide with 5-
phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, which is the key 
step in a salvage pathway of the mammalian NAD biosynthesis[7]. NAMPT was first 
cloned by Samal et al.[8]and it was originally named pre-B-cell colony enhancing factor 
(PBEF) because it can promote the maturation of pre-B-cells. NAMPT was also called 
visfatin because it is an adipokine highly produced by visceral fat and it displayed insulin 
mimetic functions [9] though the latter claim was disputed in literature. In this chapter, 
NAMPT and PBEF are used interchangeably in some parts. Jia et al. [10] from University 
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of Toronto, Canada, first reported that NAMPT mRNA in neutrophils from critically ill 
septic patients was expressed at higher levels than those in controls. Our previous study 
at Johns Hopkins University, USA, discovered that a susceptible haplotype GC in the 
promoter of human NAMPT gene had a 4.84-fold higher risk of sepsis while a potential 
protective haplotype TT had a lower risk of sepsis in a Caucasian patient population [11]. 
Bajwa et al. [12] from Massachusetts General Hospital, Harvard University, USA, 
replicated and extended our findings that the NAMPT-1001T>G variant allele and related 
haplotype were associated with increased odds of developing acute respiratory distress 
syndrome (ARDS), which is frequently associated with severe sepsis, and increased 
hazard of intensive care unit mortality among at-risk patients, whereas the -1535C>T 
(originally labeled as -1543C>T) variant allele and related haplotype are associated with 
decreased odds of ARDS among patients with septic shock and better outcomes among 
patients with ARDS. Molecular mechanisms underlying these associations have been 
actively explored. The first part of this chapter introduces the physiological functions of 
the NAMPT gene. The second part of this chapter synopsize the clinical investigation and 
epidemiological studies of NAMPT in sepsis. The third part describes our current 
understanding of molecular mechanisms underlying NAMPT in sepsis. The final part of 
this chapter includes a brief summary and some perspectives on exploring Terra Ignota of 
NAMPT in sepsis.  
2. Physiological functions of the NAMPT gene 
This section briefly introduces the three major functions of the NAMPT: Growth Factor, 
Cytokine and Nicotinamide phosphoribosyltransferase [13]. Accumulating evidence sug-
gests that NAMPT can function as a growth factor or a cytokine though the underlying 
molecular mechanisms remain to be established.  It is beyond the dispute that NAMPT can 
function as a Nicotinamide phosphoribosyltransferase.  
Growth Factor. Several studies indicate that NAMPT may function as a growth factor. Samal 
et al.[8] first found that conditional medium from COS7 or PA317 cells transiently express-
ing human NAMPT can significantly enhance the number of pre-B-cell colonies derived 
from normal human or mouse bone marrow by at least 70% in the presence of both IL-7 and 
stem cell factor. Similar observation was obtained using the antibody purified NAMPT 
protein. Thus, the authors first named this protein as pre-B-cell colony enhancing factor. 
Van der Veer et al.[14] reported that NAMPT can promote vascular smooth muscle cell 
maturation. They found that knockdown of endogenous NAMPT increased smooth muscle 
cell apoptosis and reduced the capacity of synthetic smooth muscle cells to mature to a con-
tractile state. On the other hand, human smooth muscle cells transduced with the NAMPT 
gene had enhanced survival, an elongated bipolar morphology, and increased levels of h-
caldesmon, smoothelin-A, smoothelin-B, and metavinculin. Fukuhara and co-workers [9] 
proposed NAMPT as a Visfatin, an adipokine produced by visceral fat that can engage and 
activate the insulin receptor. Although this publication was retracted because of questions 
regarding the reproducibility of the NAMPT/ insulin receptor interaction from different 
preparations of recombinant NAMPT protein[15]. Xie et al.[16] found that NAMPT exerts an 
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insulin-like activity as a growth factor for osteoblasts. They used the recombinant human 
NAMPT provided by Axxora Life Sciences (San Diego, CA, USA) in their experiments. They 
noticed that the effects of NAMPT such as glucose uptake, proliferation, and type I collagen 
enhancement in cultured human osteoblast-like cells bore a close resemblance to those of 
insulin and were inhibited by hydroxy-2-naphthalenylmethylphosphonic acid tris-
acetoxymethyl ester, a specific inhibitor of IR tyrosine kinase activity. They also unexpected-
ly found that NAMPT downregulated osteocalcin secretion from human osteoblast-like 
cells. These data indicate that the regulation of glucose uptake, proliferation, and type I 
collagen production by NAMPT in human osteoblasts involves insulin receptor phosphory-
lation, the same signal transduction pathway used by insulin. 
Cytokine. NAMPT may be added to the list of cytokines. The first NAMPT cDNA was 
screened out using a degenerate oligonucleotide probe designed on the basis of the 
similarity in the coding sequences of five different cytokines: GM-CSF, IL-2, IL-1, IL-6 and 
IL-13, at the signal peptidase processing site though the DNA or protein sequence of 
NAMPT bears no homology to other known cytokines[8]. Ognjanovic et al.[17]  reported 
that lipopolysaccharide, IL-1, TNF  and IL-6 all significantly increased the expression of 
NAMPT in a 4 h treatment of the amniotic epithelial cell line, WISH cells. The addition of 
dexamethasone to IL-1 and TNF significantly reduced the response to these cytokines. 
They concluded that NAMPT is a cytokine expressed in the normal fetal membranes and 
up-regulated when they are infected. NAMPT expression is up-regulated in a variety of 
acute and chronic inflammatory diseases including sepsis[10], acute lung injury [11], 
rheumatoid arthritis [18], inflammatory bowel disease[19], and myocardial infarction [20] 
and plays a key role in the persistence of inflammation through its capacity to inhibit 
neutrophil apoptosis[10]. rhNAMPT treatment of WISH cells and fetal membrane explants 
significantly increased IL-6 and IL-8 gene expression[21]. We also found that an 
overexpression of NAMPT significantly augmented IL-8 secretion and mRNA expression 
in A549 cells, a human pulmonary carcinoma type II epithelial cell line and human 
pulmonary artery endothelial cells. It also significantly augmented IL-1-mediated cell 
permeability. The opposite results were obtained with the knockdown of NAMPT 
expression. NAMPT expression also affected the expression of two other inflammatory 
cytokines (IL-16 and CCR3 genes) [22, 23]. Hong et al.[24]  demonstrated recombinant 
human NAMPT as a direct rat neutrophil chemotactic factor in in vitro studies. They also 
demonstrated a marked increase in bronchoalveolar lavage leukocytes after the 
intratracheal injection of rhNAMPT into C57BL/6J mice. Thus, NAMPT behaves like a 
chemokine. 
Nicotinamide phosphoribosyl transferase. The clue that PBEF could be a nicotinamide phos-
phoribosyl transferase was first obtained by the work of Martin et al.[25] in 2001. They 
demonstrated that the presence of the nadV gene allowed A. pleuropneumoniae to utilize 
nicotinamide mononucleotide as a precursor for NAD biosynthesis, and indicate that the 
enzyme encoded by this gene is a novel NAMPT. They found that the sequence of nadV 
gene is homologous to that of human NAMPT, suggesting that mammalian PBEF may 
also function as a NAMPT. Rongvaux et al.[26] verified that similarly to its microbial 
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counterpart, PBEF is a NAMPT, catalyzing the condensation of nicotinamide with 5-
phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, an intermediate 
in the biosynthesis of NAD (Figure 1). The role of PBEF as a NAMPT was further con-
firmed by showing that the mouse gene was able to confer the ability to grow in the ab-
sence of NAD to a NAMPT-defective bacterial strain. Study by Revollo et al.[7]  demon-
strated that NAMPT catalyzes a rate-limiting step in a salvage pathway of the mammalian 
NAD biosynthesis. Van der Veer et al.[27] proved that it is due to the enhanced NAMPT 
activity of PBEF that cellular lifespan of human primary smooth muscle cells, human 
clonal smooth muscle cells, and fibroblasts derived from a patient with Hutchinson-
Gilford progeria syndrome can be lengthened. Recent work by Revollo et al [33] revealed 
that NAMPT regulates insulin secretion in beta cells as a systemic NAD biosynthetic en-
zyme. 
 
Figure 1. Mammalian salvage pathway of NAD+ synthesis mediated by nicotinamide phosphoribo-
syltransferase. Nicotinamide, either derived from the degradation of NAD+ by NAD+ consuming en-
zymes or provided in the diet, is condensed with 5-phosphoribosyl-1-pyrophosphate to yield nicotina-
mide mononucleotide under the catalysis of nicotinamide phosphoribosyltransferase. Nicotinamide 
mononucleotide is then adenylylated to form NAD+, by Nicotinamide mononucleotide adenylyltrans-
ferase. NAD+ and NADH can be interconverted by a reduction and a oxidation reaction, respectively. 
This figure is copied from Zhang et al. (7). 
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Because the salvage pathway of NAD synthesis is much more efficient and quicker one than 
that of de novo NAD synthesis, it is conceivable that NAMPT plays an important role in 
varieties of physiological processes in life via the synthesis of NAD. NAD is now regarded 
as a universal energy- and signal-carrying molecule[28, 29]. Recent research has unraveled 
an unexpectedly wide array of signaling pathways that involve nicotinamide adenine 
dinucleotide (NAD) and its phosphorylated form, NADP. NAD serves as substrate for 
protein modification including protein deacetylation and mono- and poly-ADP-ribosylation. 
Both NAD and NADP represent precursors of intracellular calcium-mobilizing molecules. It 
is now well accepted that NAD (P)-mediated signal transduction does not merely regulate 
metabolic pathways but might hold a key position in the control of fundamental cellular 
processes. In mammals, it has been shown recently that an NAD-dependent protein 
deacetylase, silent information regulator (SIR) T1/2, plays important roles in a variety of 
biological processes, such as stress and cytokine responses[30], by deacetylating 
transcriptional regulators. Endogenous mono-ADP-ribosylation in higher eukaryotes 
appears to modulate the immune response, cell adhesion, signal, and energy 
metabolism[31]. Recently, defensin-1, an antimicrobial arginine-rich protein secreted by 
immune cells, was demonstrated to lose its antimicrobial effect after its mono-ADP-
ribosylation. Poly-ADP-ribosylation of proteins such as NFkB by poly-ADP-ribose 
polymerase can trigger the release of apoptosis-inducing factor from mitochondria and 
therefore effectively mediate apoptosis. Gerth et al.[32] demonstrated that NAD and ADP-
ribose, generated from NAD by CD38, an NAD-glycohydrolase, induce the activation of a 
Ca2+ channel through a pathway that involves Ca2+ influx in human monocytes. Ca2+ ions 
play a critical role in variety of monocyte functions such as chemotaxis and production of 
cytokine (TNF)[33]. Increased intracellular calcium in human monocyte-derived 
macrophages in vitro by loading with the basic calcium phosphate microcrystals was 
associated with secretion of proinflammatory cytokines (TNF, IL-1β, and IL-8) capable of 
activating cultured endothelial cells and promoting capture of flowing leukocytes under 
shear flow[34]. 
3. Role of NAMPT in Sepsis 
Because of its pleiotropic functions, NAMPT has been implicated in various human 
diseases[13] including sepsis. Increasing evidence indicates that NAMPT is a risk factor in 
sepsis. Jia et al. [10] determined the expression of PBEF in neutrophils harvested from 16 
critically ill septic patients in an intensive care unit. They found that neutrophils from these 
patients showed marked expression of PBEF mRNA.  PBEF expression was significantly 
greater in neutrophils from septic patients than in resting neutrophils or LPS-stimulated 
neutrophils from healthy volunteers. Lee et al. [35]  determined the clinical correlates for 
elevated plasma PBEF upon intensive care unit admission for severe sepsis and the useful-
ness of NAMPT to predict sepsis mortality. Plasma collected within 24 h of intensive care 
unit admission was measured for NAMPT concentrations by enzyme-linked immuno-
sorbent assay. They reported that elevated PBEF levels significantly correlated with higher 
Acute Physiology and Chronic Health Evaluation III scores (R(2) = 0.08, P = .003). The higher 
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Acute Physiology and Chronic Health Evaluation III score indicates more severe diseased 
status. Non-survivors had higher PBEF levels than survivors (2.53 ng/mL; interquartile 
range [IQR], 1.07-8.16 vs 1.44 ng/mL; IQR, 0.84-2.81; P = .02). They concluded that NAMPT 
was associated with sepsis mortality mainly due to its association with greater severity of 
illness on intensive care unit admission. Cekmez  et al. [36] found that plasma NAMPT level 
was significantly higher in septic infants than in healthy ones. There was a positive correla-
tion between NAMPT and other markers (white blood cells, C-reactive protein, procalcitonin 
and IL-6) for sepsis. A cut-off value of 10 ng/mL for NAMPT showed 92% sensitivity and 
94% specificity in the diagnosis of sepsis. Thus, the authors proposed that NAMPT could be 
used as a diagnostic marker similar to C-reactive protein, procalcitonin and IL-6 in neonatal 
sepsis. 
In our previous genetic epidemiological study [11], we determined the frequencies of minor 
alleles, genotypes and haplotypes of two human NAMPT gene promoter SNPs [-1001T>G 
and -1535C>T (originally labeled as -1543C>T)] in Caucasian septic patients and Caucasian 
healthy subjects.  We found that the frequency of the minor G allele of the SNP -1001T>G 
was significantly higher (23%) in septic patients than in healthy subjects (12%, p=0.01). 
Similarly, the frequency of its genotype GT was significantly higher (44%) in septic patients 
than in healthy subjects (20%, p=0.004). The haplotype-weighted analysis of these two SNPs 
indicated that a susceptible haplotype GC had a 4.84-fold higher risk of sepsis while a 
potential protective haplotype TT had a lowest risk of sepsis in a Caucasian patient 
population among four haplotypes: GC, GT, TC and TT. Our findings were validated and 
extended in a different patient cohort by Bajwa et al. [12]. They genotyped the NAMPT T-
1001G and C-1543T polymorphisms in 375 patients with ARDS, a frequent consequence of 
sepsis, and 787 patients at risk for developing ARDS. It was found that among the 397 
patients with sepsis syndrome, the odds of developing ARDS were significantly increased 
by presence of T-1001G and among the 561 patients with septic shock, the odds of 
developing ARDS for patients with C-1543T were significantly decreased. Overall, the 
NAMPT T-1001G variant allele and related haplotype are associated with increased odds of 
developing ARDS and increased hazard of intensive care unit mortality among at-risk 
patients, whereas the C-1543T variant allele and related haplotype are associated with 
decreased odds of ARDS among patients with septic shock and better outcomes among 
patients with ARDS. These results support that NAMPT is a genetic risk factor for sepsis. 
4. Molecular Mechanisms of NAMPT in Sepsis 
Although the role of NAMPT in sepsis is still incompletely understood, accumulating 
evidence indicates that at least the following molecular mechanisms may in part underlie 
NAMPT in sepsis (Figure 2).  
Augment expressions of other inflammatory cytokines. Sepsis is also known as a systemic 
inflammatory response syndrome caused by the body’s response to infection [1]. Systemic 
inflammation is a hallmark of sepsis. During the early stage or mild inflammatory response 
phase of sepsis, a controlled production of proinflammatory cytokines triggers beneficial 
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inflammatory responses to confine the infection and tissue damage. However, the 
protracted, excessive production of inflammatory cytokines causes capillary leakage, tissue  
 
Figure 2. Working mechanisms underlying NAMPT in the pathogenesis of sepsis.  During sepsis or 
prelude to sepsis, bacterial infection or other inflammatory stimuli excessively augment NAMPT ex-
pression, which in turn induces an excessive production of other inflammatory cytokines  such as TNF 
and IL1-. Dysregulated NAMPT also affects the number and function of neutrophils in one of three 
ways: 1. inhibiting neutrophills' apoptosis and thus prolonging neutrophil's survival; 2. priming neu-
trophils for increased ROS generation; 3. acting as a chemotactic factor to neutrophils. Prolonged and 
increased neutrophils can lead to excessive ROS production. Both excessive expression of inflammatory 
cytokines and excessive generation of ROS contribute to unwanted side effects such as cell or tissue 
damage and organ failure in sepsis.   
injury, and lethal multiple organ failure in severe sepsis [37]. NAMPT was considered as an 
inflammatory cytokine [21]. Elevated plasma NAMPT level was associated with sepsis mor-
tality [10, 35]. Elevated NAMPT may augment expressions of other inflammatory cytokines 
and thus aggravate inflammation, which in part contribute to increased severity and mortal-
ity in patients with sepsis.  
Besides sepsis, NAMPT expression is up-regulated in a variety of acute and chronic inflam-
matory diseases including acute lung injury, inflammatory bowel disease, myocardial in-
farction, and rheumatoid arthritis[13]. It have been demonstrated in vitro, that other inflam-
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matory stimuli can increase the expression of NAMPT gene. Ognjanovic et al.[17] reported 
that lipopolysaccharide, IL-1β, TNF α and IL-6 all significantly increased the expression of 
NAMPT in a 4 h treatment of the amniotic epithelial cell line, WISH cells. The addition of 
dexamethasone significantly reduced the response to IL-1β and TNFα. They concluded that 
NAMPT is expressed in the normal fetal membranes and up-regulated when they are infect-
ed. NAMPT can also stimulate the expression of other inflammatory cytokines. The rhN-
AMPT treatment of WISH cells and fetal membrane explants significantly increased IL-6 
and IL-8 gene expression[21]. We also found that an overexpression of NAMPT significantly 
augmented IL-8 secretion and mRNA expression in both human pulmonary carcinoma type 
II epithelial cell line (A549) and human pulmonary artery endothelial cells. It also signifi-
cantly augmented IL-1β-mediated cell permeability. The opposite results were obtained 
with the knockdown of NAMPT expression. NAMPT expression also affected the expres-
sion of two other inflammatory cytokines (IL-16 and CCR3 genes)[23, 38]. Our further inves-
tigation found that PBEF stimulated expression of IL-8, IL-16, and CCR3 via its non-
enzymatic activity. This effect is AP-1-dependent, in part via the p38 MAPK pathway and 
the JNK pathway[22]. From these results, it can be reasoned that infection in sepsis can in-
duce the expression of NAMPT gene, which in turn stimulate the expression of other in-
flammatory cytokines, thus aggravating inflammation in sepsis. 
Increase number of activated neutrophils. Neutrophils play important roles in host defense 
against all classes of infectious agents but, paradoxically, they are also involved in the pa-
thology of various inflammatory conditions.  Although destruction of infectious agents by 
neutrophils occurs intracellularly, release of cytotoxic molecules into the extracellular milieu 
can damage body tissues. Thus, neutrophils is a  double-edged sword [39]. Neutrophilia is a 
prominent feature in sepsis and many lines of evidence link activated neutrophils to the 
organ injury of sepsis [40]. Jia et al. [10] reported that NAMPT plays a requisite role in the 
delayed neutrophil apoptosis of clinical and experimental sepsis. They found that transcrip-
tion of the NAMPT gene is increased in neutrophils from septic patients; prevention of 
NAMPT translation through the use of an antisense oligonucleotide largely restores the 
normal kinetics of apoptosis. Moreover, the incubation of quiescent neutrophils from 
healthy volunteers with recombinant NAMPT results in dose-dependent inhibition of apop-
tosis, and antisense NAMPT prevents the inhibition of apoptosis that results from exposure 
to LPS or to a variety of host-derived inflammatory cytokines. They postulated that this 
prolonged survival of activated neutrophils may be linked to sustained inflammation and 
the organ injury of sepsis. 
The potent antimicrobial activity by neutrophils is effected through proteolytic enzymes and 
the generation of reactive oxygen species (ROS). ROS released by neutrophils are also impli-
cated in the bystander tissue injury that accompanies an inflammatory response.  Malam et 
al. [41] demonstrated that NAMPT can prime neutrophils for increased ROS generation 
through the NADPH oxidase. NAMPT promoted membrane translocation of cytosolic 
NADPH oxidase subunits p40 and p47, but not p67, induced p40 phosphorylation on 
Thr154, and activated the small GTPase Rac. Priming, translocation, and phosphorylation 
were dependent on activation of p38 and ERK MAPKs, but not of PI3K. Priming by NAMPT 
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occurred independently of its NAD-generating capacity because neither nicotinamide mon-
onucleotide nor NAD could recapitulate the effects, and a specific inhibitor of NAMPT, 
APO-866, could not inhibit priming. This  represents another molecular mechanism under-
lying NAMPT in the pathogenesis of sepsis, in which increased expression of NAMPT con-
tributes to tissue damage by priming neutrophils to produce excessive ROS.  
In a different study, Hong et al. [24] demonstrated recombinant human NAMPT as a direct 
rat neutrophil chemotactic factor in in vitro studies. They also demonstrated a marked 
increase in bronchoalveolar lavage leukocytes after the intratracheal injection of rhNAMPT 
into C57BL/6J mice in an acute lung injury model. Organ failure is frequently associated 
with severe sepsis. Chemoattractant property of NAMPT may also in part account for its 
role of increasing or activating neutrophils in sepsis.  
5. Summary and perspective 
Increasing evidence suggest that NAMPT is a risk factor in sepsis. NAMPT is highly up-
regulated in sepsis and it has been proposed as a diagnostic marker in neonatal sepsis. It 
was associated with the severity and mortality of patients with sepsis. Genetic epidemiolog-
ical studies found that a susceptible haplotype GC in the promoter of human NAMPT gene 
had a 4.84-fold higher risk of sepsis while a potential protective haplotype TT had a lower 
risk of sepsis in a Caucasian patient population. Those findings indicate that NAMPT is a 
potential genetic marker in sepsis. A few molecular mechanisms may underlie role of 
dysregulated NAMPT in the pathogenesis of sepsis. Infection in sepsis can induce the ex-
pression of NAMPT gene, which in turn stimulate the expression of other inflammatory 
cytokines, thus aggravate inflammation in sepsis. Prolonged survival of activated neutro-
phils by NAMPT via its inhibition of neutrophil apoptosis may be linked to sustained in-
flammation and the organ injury during sepsis. NAMPT can act as a chemoattractant to 
neutrophils. Increased expression of NAMPT in sepsis may also contribute to tissue damage 
by priming neutrophils to produce excessive ROS. 
It remains to be fully elucidated that role of NAMPT in sepsis may be a "double-edged 
sword". Although accumulated evidence as synopsized in this chapter and summarized in 
the above paragraph indicates that excessive up-regulation of NAMPT expression in sepsis 
contributes to excessive inflammation and tissue damage in sepsis, emerging evidence also 
suggests that a modest increase of NAMPT expression in early phase may be of beneficial 
value. A recent study by Liu et al. [42] suggested that TLR signaling might increase cellular 
NAD+ by inducing Nampt expression, which could thereby provide substrate for SIRT1 
deacetylase activity. SIRT1 deacetylates RelA/p65 lysine 310 and nucleosomal histone H4 
lysine 16 to promote termination of NFκB-dependent transcription, which results in the 
attenuation of inflammatory response.  Thus, Nampt activity promotes endotoxin tolerance. 
Therapeutic potential of NAMPT inhibitions to sepsis has not been pursued clinically 
though several basic and translational studies pointed to the possibility. Jia et al. [10] 
demonstrated that the NAMPT antisense oligonucleotide prevented the LPS or other 
inflammatory cytokines' induced neutrophil apoptosis. In neutrophils of patients with 
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sepsis, addition of PBEF antisense oligonucleotide resulted in a greater than twofold 
increase in rates of apoptosis. This study indicated that the antisense oligonucleotide to 
NAMPT could effectively inhibit PBEF expression. Ye et al. [11] reported a successful 
knockdown of NAMPT expression by more than 70% in human pulmonary vascular 
endothelial cells using three NAMPT stealth siRNAs in combination or individually. Our 
group also showed that a NAMPT antibody can block the function of NAMPT in a mouse 
model [24]. Several chemical inhibitors of NAMPT such as FK866 (also called APO866 or 
WK175, (E)-N-[4-(1-benzoylpiperidin-4-yl) butyl]-3-(pyridin-3-yl)) and related compounds 
have been tested to inhibit tumor cell growth [43] and in clinical trials as an anticancer 
agent [44]. Montecucco et al [45] recently showed that treatment with FK866 reduced 
myocardial infarct size, neutrophil infiltration and ROS generation within infarcted hearts 
in vivo in a mouse model of ischemia and reperfusion. It is of interest to explore the 
therapeutic potential of all these NAMPT inhibitory reagents to sepsis in the clinical 
setting. 
It is anticipated that further elucidation of the role and mechanisms of NAMPT in sepsis will 
enhance our understanding of molecular pathogenesis underlying NAMPT in sepsis and lead 
to the development of the NAMPT based strategy and management of sepsis in the future. 
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